Skip to content
Biodatica
Start free

National Health Research Institutes, Taiwan

Taipei

OncologyantibodyPhase III
Compare Sign in to watch

What changed

Phase II trial registered: Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer.

2w agoTrial registeredJul 2, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

672 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Dec 1, 2026

    Advanced Biliary Tract Cancer(BTC) · WITHDRAWN · sponsor: National Health Research Institutes, Taiwan · Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer.

    ClinicalTrials.gov · NCT07369791 (opens the source filing in a new tab)

  2. Trial

    PHASE3 registered

    Dec 16, 2025

    Nasopharyngeal Cancinoma (NPC), Radiation-induced Oral Mucositis · RECRUITING · sponsor: Sun Yat-sen University · Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid

    ClinicalTrials.gov · NCT07311772 (opens the source filing in a new tab)

  3. Trial

    PHASE3 registered

    Nov 20, 2025

    Nasopharyngeal Carcinoma · RECRUITING · sponsor: Ming-Yuan Chen · 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma

    ClinicalTrials.gov · NCT07328854 (opens the source filing in a new tab)

  4. Trial

    PHASE3 registered

    Aug 20, 2025

    Nasopharyngeal Carcinoma (NPC) · RECRUITING · sponsor: Ming-Yuan Chen · Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer

    ClinicalTrials.gov · NCT07188584 (opens the source filing in a new tab)

  5. Trial

    PHASE2 registered

    Jun 24, 2025

    Recurrent or Metastatic Nasopharyngeal Carcinoma · RECRUITING · sponsor: Ming-Yuan Chen · Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

    ClinicalTrials.gov · NCT07070479 (opens the source filing in a new tab)

  6. Trial

    Study registered

    Nov 14, 2024

    Nasopharyngeal Carcinoma (NPC), Screening · ACTIVE_NOT_RECRUITING · sponsor: Ming-Yuan Chen · "Xijiang Project" Screening Cohort for NPC

    ClinicalTrials.gov · NCT06787456 (opens the source filing in a new tab)

  7. Trial

    PHASE2 registered

    Jul 20, 2024

    Recurrent or Metastatic Nasopharyngeal Carcinoma · RECRUITING · sponsor: Ming-Yuan Chen · Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC

    ClinicalTrials.gov · NCT06472713 (opens the source filing in a new tab)

  8. Trial

    PHASE3 registered

    Jun 1, 2021

    Nasopharyngeal Carcinoma · RECRUITING · sponsor: Sun Yat-sen University · Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma

    ClinicalTrials.gov · NCT04944914 (opens the source filing in a new tab)

  9. Trial

    NA registered

    Jun 30, 2020

    Surgery, Recurrent Nasopharyngeal Carcinoma · RECRUITING · sponsor: Sun Yat-sen University · Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma

    ClinicalTrials.gov · NCT04425265 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources